316 results on '"Yuspa, Stuart H."'
Search Results
2. Crosstalk between tumour and stroma modifies CLIC4 cargo in extracellular vesicles
3. Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
4. Data from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
5. Table S3 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
6. Supplemental Figures 1-3 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
7. Table S2 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
8. Table S1 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
9. Table S3 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
10. Table S5 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
11. Table S1 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
12. Table S4 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
13. Data from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
14. Supplemental Figures 1-3 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
15. Table S5 from T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
16. Data from Modeling the Transcriptional Consequences of Epidermal Growth Factor Receptor Ablation in Ras-Initiated Squamous Cancer
17. Supplementary Table Legends 1-4, Figure Legends 1-2 from Modeling the Transcriptional Consequences of Epidermal Growth Factor Receptor Ablation in Ras-Initiated Squamous Cancer
18. Supplementary Tables 1-4, Figure 1-2 from Modeling the Transcriptional Consequences of Epidermal Growth Factor Receptor Ablation in Ras-Initiated Squamous Cancer
19. Supplementary Table Legends 1-4, Figure Legends 1-2 from Modeling the Transcriptional Consequences of Epidermal Growth Factor Receptor Ablation in Ras-Initiated Squamous Cancer
20. Supplementary Tables 1-4, Figure 1-2 from Modeling the Transcriptional Consequences of Epidermal Growth Factor Receptor Ablation in Ras-Initiated Squamous Cancer
21. Data from S100A7 Enhances Mammary Tumorigenesis through Upregulation of Inflammatory Pathways
22. Data from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
23. Supplementary Figure 5 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
24. Supplementary Table 1 from S100A7 Enhances Mammary Tumorigenesis through Upregulation of Inflammatory Pathways
25. Supplementary Figure 5 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
26. Supplementary Figure 7 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
27. Supplementary Figure 3 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
28. Data from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
29. Supplementary Table 1 from S100A7 Enhances Mammary Tumorigenesis through Upregulation of Inflammatory Pathways
30. Supplementary Figure 4 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
31. Data from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
32. Data from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
33. Supplementary Figure 1 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
34. Supplementary Figure 1 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
35. Supplementary Figure 1 from S100A7 Enhances Mammary Tumorigenesis through Upregulation of Inflammatory Pathways
36. Supplementary Figures 1-3 from Inducible Cutaneous Inflammation Reveals a Protumorigenic Role for Keratinocyte CXCR2 in Skin Carcinogenesis
37. Supplementary Legends for Tables 1-2, Figures 1-7, Methods from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
38. Supplementary Figures 1-5, Tables 1-2 from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
39. Supplementary Figures 1-3 from Inducible Cutaneous Inflammation Reveals a Protumorigenic Role for Keratinocyte CXCR2 in Skin Carcinogenesis
40. Supplementary Methods and Materials from Activator Protein-1 Activity Regulates Epithelial Tumor Cell Identity
41. Supplementary Legends for Tables 1-2, Figures 1-7, Methods from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
42. Supplementary Figures 1-5, Tables 1-2 from The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature
43. Data from S100A7 Enhances Mammary Tumorigenesis through Upregulation of Inflammatory Pathways
44. Data from Inducible Cutaneous Inflammation Reveals a Protumorigenic Role for Keratinocyte CXCR2 in Skin Carcinogenesis
45. Supplementary Figure 2 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
46. Supplementary Methods and Materials from Activator Protein-1 Activity Regulates Epithelial Tumor Cell Identity
47. Supplementary Figure 2 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
48. Data from Inducible Cutaneous Inflammation Reveals a Protumorigenic Role for Keratinocyte CXCR2 in Skin Carcinogenesis
49. Supplementary Figure 3 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
50. Supplementary Figure 6 from RasGRP3 Contributes to Formation and Maintenance of the Prostate Cancer Phenotype
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.